WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol.2, 2008. ,
CNS involvement and treatment with interferon-a are independent prognostic factors in ErdheimChester disease: a multicenter survival analysis of 53 patients, Blood, vol.117, issue.10, pp.2778-2782, 2011. ,
Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, vol.116, issue.11, pp.1919-1923, 2010. ,
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, J Exp Med, vol.211, issue.4, pp.669-683, 2014. ,
BRAF mutations in Erdheim-Chester disease, J Clin Oncol, vol.31, issue.3, p.398, 2013. ,
High prevalence of BRAF V600E mutations in ErdheimChester disease but not in other non-Langerhans cell histiocytoses, Blood, vol.120, issue.13, pp.2700-2703, 2012. ,
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Blood, vol.121, issue.9, pp.1495-1500, 2013. ,
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease, 2014. ,
, Ann Rheum Dis
Somatic activating ARAF mutations in Langerhans cell histiocytosis, Blood, vol.123, issue.20, pp.3152-3155, 2014. ,
Detection of an NRAS mutation in ErdheimChester disease, Blood, vol.122, issue.6, pp.1089-1091, 2013. ,
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, issue.1, pp.94-100, 2013. ,
BRAFV600E Mutation in a Histiocytic Sarcoma Arising From Hairy Cell Leukemia, 2014. ,
, J Clin Oncol
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping, J Mol Diagn, vol.13, issue.1, pp.64-73, 2011. ,
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers, PLoS ONE, vol.6, issue.7, p.22769, 2011. ,
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies, Cancer Discov, vol.4, issue.5, pp.538-545, 2014. ,
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, Lancet Oncol, vol.14, issue.3, pp.249-256, 2013. ,
METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, vol.367, issue.2, pp.107-114, 2012. ,
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res, vol.69, issue.1, pp.143-150, 2009. ,
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/ mTOR inhibitors, Cell Reports, vol.6, issue.2, pp.377-387, 2014. ,
Evaluation of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis, Blood, vol.122, p.2907, 2013. ,
Sirolimus plus prednisone for Erdheim-Chester disease: a pilot trial, Rheumatology Annual Meeting, p.789, 2013. ,